Work

Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers

Year: 2018

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2018.04.069

Authors: A.R. Mallen, V.L. Filiaci, D.A. Levine, K. Thiel, C.A. Aghajanian, X. Meng, E. Devor, K.N. Moore, M.A. Powell, A.A. Secord, K.S. Tewari, D.P. Bender, A.R. Stuckey, J.M. Fowler, S.B. Dewdney, K.K. Leslie

Institutions: Moffitt Cancer Center, New York University, University of Iowa, Weill Cornell Medicine, University of Iowa Hospitals and Clinics, University of Oklahoma Health Sciences Center, Washington University in St. Louis, Duke University, Duke Cancer Institute, University of California, Irvine Medical Center, Brown University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Rush University Medical Center

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2810084179

FWCI: 1.453

Cites:

Cited by: 8

Related to: 10